Eckert & Ziegler Past Earnings Performance
Past criteria checks 4/6
Eckert & Ziegler has been growing earnings at an average annual rate of 9.6%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 10.3% per year. Eckert & Ziegler's return on equity is 14.7%, and it has net margins of 12.9%.
Key information
9.6%
Earnings growth rate
9.3%
EPS growth rate
| Medical Equipment Industry Growth | 4.3% |
| Revenue growth rate | 10.3% |
| Return on equity | 14.7% |
| Net Margin | 12.9% |
| Next Earnings Update | 27 Mar 2025 |
Recent past performance updates
Recent updates
Eckert & Ziegler SE's (ETR:EUZ) Share Price Could Signal Some Risk
Aug 08
Does Eckert & Ziegler (ETR:EUZ) Have A Healthy Balance Sheet?
Jul 17Why We Think Eckert & Ziegler SE's (ETR:EUZ) CEO Compensation Is Not Excessive At All
Jun 20Investors Met With Slowing Returns on Capital At Eckert & Ziegler (ETR:EUZ)
Jun 05Is Now An Opportune Moment To Examine Eckert & Ziegler SE (ETR:EUZ)?
May 13Eckert & Ziegler SE (ETR:EUZ) Investors Are Less Pessimistic Than Expected
Apr 27Here's Why Eckert & Ziegler (ETR:EUZ) Can Manage Its Debt Responsibly
Apr 12Slowing Rates Of Return At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Leave Little Room For Excitement
Mar 06What Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) P/E Is Not Telling You
Jan 04Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has A Pretty Healthy Balance Sheet
Dec 20Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Hasn't Managed To Accelerate Its Returns
Nov 15What Is Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) Share Price Doing?
Oct 01A Look At The Intrinsic Value Of Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)
Aug 22These 4 Measures Indicate That Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is Using Debt Reasonably Well
Jul 16Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 22The Return Trends At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Look Promising
May 17Is Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) Potentially Undervalued?
Mar 20Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns Have Hit A Wall
Jan 24We Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Can Stay On Top Of Its Debt
Oct 27Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Oct 05Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has Some Way To Go To Become A Multi-Bagger
Aug 21Is Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) A Risky Investment?
Jul 21Is There Now An Opportunity In Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 13Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Will Pay A Larger Dividend Than Last Year At €0.50
May 13Returns At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Are On The Way Up
May 09Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Dividend Will Be Increased To €0.50
Apr 24Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Dividend Will Be Increased To €0.50
Mar 27Do Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Earnings Warrant Your Attention?
Mar 25When Should You Buy Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Feb 17Investors Will Want Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Growth In ROCE To Persist
Jan 31Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today
Dec 13Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns On Capital Are Heading Higher
Nov 01Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today
Sep 14Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Have The Makings Of A Multi-Bagger
Jul 29Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is An Interesting Stock
Jun 11Revenue & Expenses Breakdown
How Eckert & Ziegler makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 278 | 36 | 69 | 0 |
| 30 Jun 24 | 274 | 38 | 69 | 0 |
| 31 Mar 24 | 256 | 34 | 66 | 0 |
| 31 Dec 23 | 246 | 30 | 64 | 0 |
| 30 Sep 23 | 240 | 33 | 60 | 0 |
| 30 Jun 23 | 233 | 29 | 59 | 0 |
| 31 Mar 23 | 230 | 30 | 59 | 0 |
| 31 Dec 22 | 222 | 31 | 58 | 0 |
| 30 Sep 22 | 215 | 27 | 61 | 0 |
| 30 Jun 22 | 198 | 27 | 58 | 0 |
| 31 Mar 22 | 186 | 27 | 56 | 0 |
| 31 Dec 21 | 180 | 35 | 54 | 0 |
| 30 Sep 21 | 180 | 33 | 57 | 0 |
| 30 Jun 21 | 182 | 31 | 54 | 0 |
| 31 Mar 21 | 176 | 30 | 52 | 0 |
| 31 Dec 20 | 176 | 21 | 51 | 0 |
| 30 Sep 20 | 172 | 21 | 48 | 0 |
| 30 Jun 20 | 173 | 22 | 50 | 0 |
| 31 Mar 20 | 179 | 21 | 51 | 0 |
| 31 Dec 19 | 178 | 22 | 51 | 0 |
| 30 Sep 19 | 178 | 22 | 52 | 0 |
| 30 Jun 19 | 177 | 21 | 53 | 0 |
| 31 Mar 19 | 177 | 20 | 52 | 0 |
| 31 Dec 18 | 169 | 16 | 50 | 0 |
| 30 Sep 18 | 162 | 16 | 47 | 0 |
| 30 Jun 18 | 155 | 14 | 45 | 0 |
| 31 Mar 18 | 142 | 11 | 44 | 0 |
| 31 Dec 17 | 139 | 12 | 44 | 0 |
| 30 Sep 17 | 131 | 11 | 43 | 0 |
| 30 Jun 17 | 124 | 11 | 44 | 0 |
| 31 Mar 17 | 117 | 11 | 41 | 0 |
| 31 Dec 16 | 120 | 10 | 43 | 0 |
| 30 Sep 16 | 127 | 9 | 46 | 0 |
| 30 Jun 16 | 132 | 9 | 47 | 0 |
| 31 Mar 16 | 142 | 11 | 51 | 0 |
| 31 Dec 15 | 140 | 12 | 52 | 0 |
| 30 Sep 15 | 137 | 11 | 51 | 0 |
| 30 Jun 15 | 134 | 12 | 51 | 0 |
| 31 Mar 15 | 130 | 8 | 49 | 0 |
| 31 Dec 14 | 127 | 7 | 48 | 0 |
| 30 Sep 14 | 124 | 8 | 47 | -3 |
| 30 Jun 14 | 124 | 8 | 46 | -2 |
| 31 Mar 14 | 121 | 9 | 46 | -1 |
| 31 Dec 13 | 117 | 9 | 44 | 0 |
Quality Earnings: EUZ has high quality earnings.
Growing Profit Margin: EUZ's current net profit margins (12.9%) are lower than last year (13.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EUZ's earnings have grown by 9.6% per year over the past 5 years.
Accelerating Growth: EUZ's earnings growth over the past year (10.1%) exceeds its 5-year average (9.6% per year).
Earnings vs Industry: EUZ earnings growth over the past year (10.1%) exceeded the Medical Equipment industry 10.1%.
Return on Equity
High ROE: EUZ's Return on Equity (14.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eckert & Ziegler SE is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adrian Kowollik | Dr. Kalliwoda Research |
| Alexander Galitsa | Hauck Aufhäuser Investment Banking |
| Simon Keller | Hauck Aufhäuser Investment Banking |